Zhang Jisong, Hu Huihui, Xu Shan, Jiang Hanliang, Zhu Jihong, Qin E, He Zhengfu, Chen Enguo
Department of Pulmonary and Critical Care Medicine, Sir Run Run Shaw Hospital of Zhejiang University, Hangzhou, China.
Department of Anesthesiology, Sir Run Run Shaw Hospital of Zhejiang University, Hangzhou, China.
Front Genet. 2020 Feb 4;11:17. doi: 10.3389/fgene.2020.00017. eCollection 2020.
Lung cancer is a common malignant cancer. Kirsten rat sarcoma oncogene (KRAS) mutations have been considered as a key driver for lung cancers. KRAS p.G12C mutations were most predominant in NSCLC which was comprised about 11-16% of lung adenocarcinomas (p.G12C accounts for 45-50% of mutant KRAS). But it is still not clear how the KRAS mutation triggers lung cancers. To study the molecular mechanisms of KRAS mutation in lung cancer. We analyzed the gene expression profiles of 156 KRAS mutation samples and other negative samples with two stage feature selection approach: (1) minimal Redundancy Maximal Relevance (mRMR) and (2) Incremental Feature Selection (IFS). At last, 41 predictive genes for KRAS mutation were identified and a KRAS mutation predictor was constructed. Its leave one out cross validation MCC was 0.879. Our results were helpful for understanding the roles of KRAS mutation in lung cancer.
肺癌是一种常见的恶性肿瘤。 Kirsten大鼠肉瘤致癌基因(KRAS)突变被认为是肺癌的关键驱动因素。KRAS p.G12C突变在非小细胞肺癌中最为常见,约占肺腺癌的11-16%(p.G12C占突变型KRAS的45-50%)。但KRAS突变如何引发肺癌仍不清楚。为了研究肺癌中KRAS突变的分子机制。我们采用两阶段特征选择方法分析了156个KRAS突变样本和其他阴性样本的基因表达谱:(1)最小冗余最大相关性(mRMR)和(2)增量特征选择(IFS)。最后,鉴定出41个KRAS突变的预测基因,并构建了KRAS突变预测模型。其留一法交叉验证MCC为0.879。我们的结果有助于理解KRAS突变在肺癌中的作用。